Insulin Resistance: The Silent Epidemic Hiding in Plain Sight
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
Insulin resistance is the most prevalent metabolic disease in the industrialized world — present in an estimated 35–40% of normoglycemic American adults and affecting the majority of those with obesity, prediabetes, type 2 diabetes, polycystic ovary syndrome, metabolic syndrome, and nonalcoholic fatty liver disease. It is the central pathophysiologic defect underlying all of these conditions. It is detectable years to decades before any of them are formally diagnosed. And it is almost never measured at a standard annual physical.
The standard laboratory screening approach to cardiometabolic risk — fasting glucose and HbA1c — is systematically blind to insulin resistance in its early stages. This is because both tests measure the glycemic consequence of insulin resistance rather than the resistance itself. By the time fasting glucose or HbA1c crosses a diagnostic threshold, the pancreas has typically been producing compensatory hyperinsulinemia for years, and downstream metabolic consequences — atherogenic dyslipidemia, systemic inflammation, endothelial dysfunction, hypertension, and fatty liver — have been accumulating throughout that period.
This article reviews the cellular and molecular mechanisms of insulin resistance, its prevalence and clinical consequences, the available diagnostic tools and their relative strengths, the lifestyle and pharmacologic interventions with the strongest evidence for reversal, and the rationale for measuring insulin directly — rather than waiting for glucose dysregulation that appears only after the disease has been present for years.
Mechanism: Normal Insulin Signaling and Its Disruption
Normal Insulin Physiology
Insulin binds to its receptor — a tetrameric tyrosine kinase — on skeletal muscle, adipose tissue, and hepatic cells, triggering autophosphorylation and activation of insulin receptor substrate proteins (IRS-1, IRS-2). The activated IRS proteins engage the PI3K/Akt signaling pathway, which mediates the major metabolic effects of insulin:[1]
- —GLUT4 translocation: In skeletal muscle and adipose tissue, Akt phosphorylates AS160, enabling GLUT4 vesicle fusion with the plasma membrane and massively increasing cellular glucose uptake capacity
- —Hepatic glucose suppression: In the liver, Akt inhibits FOXO1 transcription factor activity, suppressing gluconeogenesis and glycogenolysis
- —Lipid metabolism: Insulin activates SREBP-1c, driving de novo lipogenesis and fatty acid esterification; it inhibits HSL (hormone-sensitive lipase), reducing adipocyte lipolysis
The Insulin Resistance Lesion
Insulin resistance is characterized by impaired responsiveness to insulin at target tissues, requiring progressively greater insulin concentrations to achieve normal metabolic effects. The molecular lesion is predominantly at the level of IRS-1/IRS-2 — both excess free fatty acids and pro-inflammatory cytokines (TNF-α, IL-6) activate serine kinases (including JNK, IKKβ, mTOR, S6K1) that phosphorylate IRS-1 at serine residues rather than the normal tyrosine residues, impairing IRS-1's ability to engage PI3K and propagate downstream signaling.[2]
The result is a hierarchical pattern of insulin resistance: some insulin actions — particularly hepatic VLDL production and sterol regulatory element-binding protein activation — remain insulin-sensitive even as other pathways become resistant. This selective hepatic insulin resistance is the mechanism by which insulin resistance simultaneously impairs hepatic glucose suppression and maintains or increases VLDL production, producing the atherogenic dyslipidemia phenotype of metabolic syndrome.
The Compensatory Phase and Its Endpoint
As peripheral insulin resistance develops, the pancreatic beta cells compensate by increasing insulin secretion — producing the hyperinsulinemia that is the most sensitive early marker of insulin resistance. This compensatory response maintains near-normal glucose levels for years, during which time HbA1c and fasting glucose remain below diagnostic thresholds. The disease is present. The standard glucose tests are normal.
“This is not the beginning of the disease. It is the visible end-stage of a process that began years or decades earlier.”
When beta-cell capacity for compensatory hyperinsulinemia is eventually exhausted — driven by lipotoxicity, glucotoxicity, and endoplasmic reticulum stress in beta cells — fasting glucose rises, HbA1c climbs, and the clinical diagnosis of prediabetes or type 2 diabetes follows. This is not the beginning of the disease. It is the visible end-stage of a process that began years or decades earlier.
Epidemiology: The Scale of the Problem
Prevalence in normoglycemic adults: Using HOMA-IR ≥ 2.5 as a threshold, approximately 35–40% of normoglycemic (fasting glucose < 100 mg/dL) adults in the United States have significant insulin resistance.[3] This is not a small proportion — it is the dominant cardiometabolic phenotype across all body weight categories.
Progression to type 2 diabetes: Approximately 70% of individuals with insulin resistance will develop type 2 diabetes in their lifetime if the underlying process is not addressed. The typical timeline from identifiable insulin resistance to frank diabetes spans 5–20 years, providing a substantial intervention window.
Relationship to cardiometabolic outcomes: The insulin resistance phenotype is associated with significantly elevated risk of cardiovascular disease, independent of lipid levels and blood pressure, through mechanisms including atherogenic dyslipidemia, systemic inflammation, endothelial dysfunction, and procoagulant effects.[4] HOMA-IR at baseline predicts subsequent cardiovascular events in prospective analyses even in non-diabetic individuals.
Prevalence by Population
Diagnostic Tools: What to Measure and What It Means
Fasting Insulin and HOMA-IR
The homeostatic model assessment of insulin resistance (HOMA-IR) is calculated as:
HOMA-IR = (fasting insulin [µIU/mL] × fasting glucose [mmol/L]) ÷ 22.5
or equivalently: (fasting insulin × fasting glucose [mg/dL]) ÷ 405
HOMA-IR was validated by Matthews et al. (1985) and requires only two values from a single fasting blood draw — glucose from the standard CMP, and insulin from a separately ordered fasting insulin assay.[5]
Clinical Thresholds
The critical clinical point: a patient with fasting glucose of 95 mg/dL (entirely normal by standard criteria) and fasting insulin of 22 µIU/mL has a HOMA-IR of 5.0. Their fasting glucose test, interpreted in isolation, would produce no clinical concern. Their HOMA-IR documents severe insulin resistance.
The LP-IR Score (NMR-Derived)
The lipoprotein insulin resistance score is a validated composite index derived from six NMR-measured lipoprotein subclass parameters: large VLDL particle concentration, small LDL particle concentration, large HDL particle concentration, VLDL size, LDL size, and HDL size. LP-IR correlates closely with clamp-measured insulin sensitivity and is generated automatically by the NMR LipoProfile report.[6]
LP-IR ≥ 45 is associated with insulin resistance by clinical convention; ≥ 60 represents the upper range of significant insulin resistance.
Triglyceride-to-HDL Ratio
The TG/HDL ratio, calculated from standard lipid panel values in mg/dL, is a widely validated clinical surrogate for the small-dense LDL particle phenotype and insulin resistance. TG/HDL > 3.5 in men and > 3.0 in women is a sensitive indicator of the atherogenic dyslipidemic phenotype associated with insulin resistance.[7]
Its clinical value lies in its accessibility: no additional tests are required beyond a standard lipid panel. A TG/HDL ratio that is calculable from data already obtained but never discussed is a missed opportunity for metabolic risk identification.
Gold Standard: Hyperinsulinemic Euglycemic Clamp
The euglycemic hyperinsulinemic clamp provides a direct measurement of whole-body insulin sensitivity as the glucose infusion rate required to prevent hypoglycemia during fixed-rate insulin infusion. It is the research gold standard against which all clinical surrogates have been validated. It requires continuous IV access and glucose monitoring for several hours and is not applicable to clinical practice.
Downstream Consequences
Atherogenic Dyslipidemia
The hepatic selective insulin resistance produces a stereotyped lipid pattern: elevated VLDL and triglycerides, low HDL, and the small-dense LDL phenotype. The standard lipid panel often appears acceptable in early insulin resistance — LDL may be in the normal range — while the NMR profile reveals elevated particle number, small-dense particles, and elevated LP-IR. This discordance is the most important practical reason for advanced lipid testing in any patient suspected of insulin resistance.
Systemic Inflammation
Hyperinsulinemia and excess free fatty acid flux activate NF-κB, driving inflammatory cytokine production (TNF-α, IL-6, IL-1β) and chronically elevating hs-CRP. The insulin-resistant patient with "acceptable" lipids and hs-CRP at 2.4 mg/L is showing the inflammatory signature of their metabolic disease.
Nonalcoholic Fatty Liver Disease (MASLD)
The liver, receiving excess free fatty acids from visceral lipolysis and driving VLDL overproduction under hyperinsulinemic conditions, accumulates triglycerides — producing steatosis. MASLD is the hepatic manifestation of insulin resistance and is present in 80–90% of patients with significant insulin resistance. GGT rises before ALT; its elevation in the context of insulin resistance markers indicates early hepatic fat accumulation.
Cardiovascular Disease
Multiple mechanisms converge: atherogenic dyslipidemia provides the substrate for plaque development; endothelial dysfunction (impaired insulin-mediated NO production) impairs vasodilatory reserve; systemic inflammation promotes plaque vulnerability; and the prothrombotic consequences of hyperinsulinemia (elevated PAI-1) increase clotting risk.
Polycystic Ovary Syndrome (PCOS)
In women with PCOS, insulin resistance — present in 60–70% regardless of BMI — drives compensatory hyperinsulinemia that stimulates ovarian androgen production, contributing to anovulation, hyperandrogenism, and the metabolic phenotype of the syndrome. Treatment of insulin resistance through lifestyle modification and metformin is a primary therapeutic strategy in PCOS.
Reversal: What the Evidence Supports
Insulin resistance is not a fixed metabolic state. It is highly responsive to intervention, and the magnitude of improvement is proportional to the comprehensiveness of the intervention.
Aerobic Exercise
The most potent acute insulin-sensitizing intervention. Skeletal muscle contraction activates AMPK — a cellular energy sensor — which drives GLUT4 translocation to the cell surface completely independently of insulin receptor signaling. This contraction-mediated glucose uptake bypasses the impaired insulin signaling pathway entirely, providing acute insulin sensitization for 24–72 hours post-exercise. With sustained training, structural improvements in skeletal muscle oxidative capacity, mitochondrial density, and GLUT4 expression produce durable improvements.[8]
Resistance Training
Increases skeletal muscle mass — the largest insulin-sensitive glucose disposal organ in the body. Every kilogram of lean mass added is a permanent increase in the body's glucose disposal capacity and resting metabolic rate. The combination of aerobic and resistance training is superior to either modality alone for insulin resistance reversal.
Dietary Carbohydrate Reduction
Reducing dietary carbohydrate — specifically refined carbohydrates and added sugars — directly reduces the postprandial insulin demand on a system that is struggling to meet it. This allows insulin levels to fall, reduces hepatic de novo lipogenesis, and enables a shift toward fatty acid oxidation. Multiple RCTs confirm that low-carbohydrate dietary interventions produce superior improvements in fasting insulin, triglycerides, and HDL compared to isocaloric low-fat approaches.
Sleep Optimization
A single night of sleep deprivation (4–6 hours) produces measurable insulin resistance the following day. Chronic short sleep elevates cortisol, elevates ghrelin, reduces leptin, and impairs glucose metabolism through multiple pathways. The insulin-resistant patient who sleeps five hours a night is continuously regenerating the insulin resistance that their exercise and diet are working to reverse.
Pharmacotherapy
Metformin: AMPK activator; reduces hepatic glucose production; modestly improves peripheral insulin sensitivity. First-line in prediabetes and T2DM; beneficial for weight management and long-term cardiovascular outcomes.
GLP-1 receptor agonists and GLP-1/GIP dual agonists: Produce profound insulin sensitization through visceral fat reduction, improved beta-cell function, and direct peripheral effects. The SURMOUNT trial with tirzepatide demonstrated 15–22% total body weight reduction and dramatic improvements in all insulin resistance parameters.[9] The STEP trial series with semaglutide confirmed similar magnitudes of metabolic improvement.
SGLT2 inhibitors: Reduce hyperglycemia and hyperinsulinemia through urinary glucose excretion, reducing the glycemic burden on a stressed system and producing modest but clinically meaningful metabolic improvements.
Conclusion
Insulin resistance is the most prevalent, most consequential, and most systematically underdiagnosed cardiometabolic condition in adult medicine. The screening tools deployed at the standard annual physical — fasting glucose and HbA1c — are specifically blind to insulin resistance in its early stages, when intervention would be most effective. By the time standard glucose tests cross diagnostic thresholds, the metabolic cascade has been running for years.
Measuring fasting insulin, calculating HOMA-IR, and incorporating the LP-IR score and TG/HDL ratio into clinical assessment transforms the detection window from the end-stage of the disease to its early, reversible phase. The interventions that reverse insulin resistance — structured exercise, carbohydrate-targeted nutrition, sleep optimization, and appropriate pharmacotherapy — address the root cause rather than its downstream manifestations. This is precision cardiometabolic medicine.
References
- 1.Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.
- 2.Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22.
- 3.Crofts CAP, Zinn C, Wheldon MC, Schofield GM. Hyperinsulinemia: a unifying theory of chronic disease? Diabesity. 2015;1(4):34–43.
- 4.Bonora E, Kiechl S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diabetes Care. 2007;30(2):318–324.
- 5.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
- 6.Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90(8A):22i–29i.
- 7.McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802–809.
- 8.Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993–1017.
- 9.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- 10.Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol Endocrinol Metab. 2011;301(5):E1033–E1040.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog